MS-associated EAA has a direct influence on income and biosecurity expenses because it increases cracked and degraded eggs, increases labour costs for sorting and cleanup and decreases hatchability through higher embryonic mortality when shell integrity is compromised. EAA manifests as irregularities at the egg’s apex, including thinning, increased translucency and susceptibility to cracks. These defects lead to increased egg breakage and spoilage, directly leading to degrading egg quality and marketability.

Etiology and Transmission:
Mycoplasma synoviae, belongs to the Mycoplasmataceae family and is fastidious about its culture conditions as it requires serum and NAD on modified Frey media. The pathogenicity of strains varies due to immune evasion, adhesins, sialidase activity, nitric oxide generation and antigenic diversity.

Fig. 1. Transmission of M. Synoviae
The host range of the MS infection includes chickens, turkeys, ducks, geese, guinea fowl, pheasants, quail and psittacines. Transmission occurs via both vertical and horizontal route. Vertical transmission takes place through transovarian infection, leading to early chick exposure, while horizontal transmission occurs via aerosol spread, respiratory secretions, fomites and human activity. Once introduced, the infection tends to persist, as infected flocks become lifelong carriers. Multi-age layer systems further support its persistence and contribute to episodic clinical outbreaks.

Pathogenesis:
M. synoviae primarily enters the host through the respiratory tract, with the upper respiratory mucosa serving as the initial site of colonization. With the help of specialized surface proteins and adhesions the organism attaches to the epithelial cells which help it to evade mucociliary clearance. From the respiratory tract, it can spread locally, causing tracheitis, airsacculitis and respiratory distress. In some birds, the pathogen disseminates via bacteraemia, reaching synovial membranes and joints, where it induces inflammation. This leads to synovitis, characterized by swelling, pain and lameness, often accompanied by exudation of yellowish synovial fluid. The organism may also localize in the tendon sheaths and bursae, producing tenosynovitis. Co-infections with other respiratory pathogens (e.g., E. coli, NDV and IBV) exacerbate disease severity. Chronic infections are common and affected birds may become carriers, serving as reservoirs for flock-to-flock transmission.

Clinical Signs:
Mycoplasma synoviae most commonly causes subclinical upper respiratory infections or infectious synovitis and tenosynovitis, while in layers it is also associated with eggshell apex abnormality (EAA) syndrome, characterized by thin, rough, translucent shell apices and intermittent production loss (Feberwee et al., 2009). The clinical expression of the disease is often expressed by stress and co-infections with pathogens such as infectious bronchitis virus (IBV), Newcastle disease virus (NDV) and Escherichia coli (Lockaby et al., 1998).

Fig.2. Dull, depressed hen, Inflammation of foot pad, hock joint and cavity filled with exudates
Affected birds may show mild respiratory involvement, including slight tracheal rales and sinusitis which are more evident under poor air quality or concurrent respiratory infections. The musculoskeletal form is marked by lameness, reluctance to walk, swelling of the hock joint, wing joints and footpads with exudative tenosynovitis of tendon sheaths and sternal bursitis. In systemic or severe cases, signs include depression, inappetence, ruffled feathers, weight loss and pale to cyanotic head parts, with occasional vasculitis and keel bursitis. Morbidity typically ranges from low to moderate, while mortality is generally low but may increase in the presence of secondary bacterial infections, wet litter, cold stress and immunosuppression.

Post Mortem Lesions:
– Respiratory tract:
– Mild to moderate airsacculitis with thickening, opacity and presence of turbid or caseous exudate.
– Mucoid tracheitis and sinusitis (especially when complicated by co-infections).
– Joints and musculoskeletal system:
– Synovitis: Swollen joints (particularly hock, wing and foot joints) with accumulation of yellow to serofibrinous exudate.
– Tenosynovitis: Inflamed tendon sheaths filled with exudate.
– Sternal bursitis (breast blisters) with fibrinous to caseous material.
– Systemic involvement:
– Generalized fibrinous polyserositis in some cases, especially with secondary E. coli infection.
– Emaciation and poor body condition due to chronic disease.
– Eggshell apex abnormality (in layers):
No specific gross lesion in reproductive tract, but post-mortem examination may reveal rough, thin and translucent apices of eggshells in affected flocks.

– Diagnosis:
Diagnosis of MS relies on combination of clinical observation, serology, microbiology and molecular techniques. Observation of respiratory signs such as sneezing, coughing and nasal discharge, along with joint or tendon swelling indicative of synovitis or tenosynovitis and specially in layers, eggshell apex abnormalities like thin, rough or translucent apexes can be observed.
However, clinical signs alone are not definitive, as they can overlap with other infections like NDV, IBV or E. coli.

Serological tests, including ELISA, rapid plate agglutination (RPA) and hemagglutination inhibition (HI), are useful for flock-level monitoring, though maternal antibodies and past exposure can complicate interpretation. Microbiological isolation from choanal or tracheal swabs and synovial fluid using specialized media allows definitive identification of MS, but the process is slow and prone to contamination. Molecular methods such as PCR and real-time PCR offer rapid, sensitive and specific detection of MS DNA, even at low bacterial loads. For accurate diagnosis, a combination of clinical assessment, serology and molecular confirmation is recommended, especially in flocks showing respiratory disease, joint swelling, or eggshell defects.

Treatment
Along with careful use of antibiotics, proper management practices and vaccination strategies are very important in Mycoplasma synoviae management. Treatment typically relies on antimicrobials such as tylosin, tiamulin, doxycycline or enrofloxacin, which can reduce bacterial load and clinical signs, but complete eradication is difficult due to intracellular persistence. Widespread and indiscriminate antibiotic use has led to antimicrobial resistance (AMR) in MS strains because of these challenges, thus, vaccination plays a central role in flock protection, lower bacterial shedding and prevent eggshell apex abnormalities in layers.

Prevention and Control:
Prevention focuses on biosecurity measures, including sourcing MS-free breeders, controlling movement of personnel and equipment and minimizing stressors that predispose birds to infection. Integrated control combining vaccination, strict biosecurity, monitoring via serology or PCR and responsible antimicrobial use is essential to minimize economic losses, maintain flock health and reduce the risk of AMR development. Thus vaccination, combined with good biosecurity and management practices can control MS spread, minimizing antibiotic reliance and maintaining flock productivity.

Stallen South Asia Pvt Ltd is offering a unique inactivated vaccine MS-VAC particularly against Mycoplasma synoviae.
Key Features of MS-VAC:
– The Only Vaccine Made from highly immunogenic strains of Mycoplasma synoviae
– High titre (1010 CFU)
– Oil adjuvant
– High immunogenicity.
– High safety, effective protection and field compatibility

Duration of immunity in MS-VAC

Fig. 5 Duration of immunity in MS-VAC (3 weeks after challenging with virulent MS)
MS-VAC is a vaccine produced from highly immunogenic strains of Mycoplasma synoviae. The culture is inactivated and emulsified in light mineral oil, to ensure a high degree of protection after first vaccination, however the immunity is strongest and long lasting after second inoculation.
– Clinical observation of eggs laid, in vaccinated and non vaccinated commercial hens, after infection by field MS.

Field efficacy of MS-VAC against eggshell apex abnormalities (EAA):

A significantly lower (p=0,000) percentage of EAA affected eggs was observed in group 1 than in groups 2 and 3 (statistically significant difference for p<0.001).
Hence, MS-VAC proved to be effective in protecting commercial hens from EAA, significantly more than the competitiors, in farms infected with MS.

References are available on request

Abstract
The Indian poultry sector is a cornerstone of the nation’s livestock economy, ensuring nutritional security, livelihood opportunities, and rural empowerment. As India advances towards the vision of Viksit Bharat 2047, strengthening animal health through modern vaccination strategies becomes imperative. Poultry production faces persistent challenges from infectious diseases such as Newcastle Disease, Infectious Bursal Disease, Marek’s Disease, Avian Influenza, and Salmonellosis, which not only cause heavy economic losses but also threaten food safety and trade opportunities. While conventional vaccines have played a pivotal role in disease control, their limitations—such as cold chain dependence, maternal antibody interference, and inadequate protection against evolving strains—demand innovative solutions.

Next-generation vaccine technologies, including recombinant DNA vaccines, vector-based vaccines, immune-complex vaccines, thermostable formulations, and in-ovo delivery systems, are transforming poultry health management. These approaches offer enhanced safety, longer-lasting immunity, and the potential for multivalent protection. Thermostable vaccines and oral or feed-based delivery methods hold special promise for rural and smallholder farmers by overcoming infrastructural constraints. Moreover, advanced vaccines contribute significantly to antimicrobial stewardship by reducing dependence on antibiotics, thereby aligning with the global One Health agenda and mitigating antimicrobial resistance risks.

The pathway to widespread adoption of these technologies requires integrated efforts from policymakers, research institutions, and the private sector. Public-private partnerships, farmer training, and targeted extension services are essential to ensure affordability, accessibility, and farmer compliance. Furthermore, harmonization with international standards will open new avenues for Indian poultry exports.

Over all next-generation poultry vaccines represent more than a disease-prevention tool; they are strategic enablers of sustainable production, food security, and global competitiveness. By embedding these innovations into a national animal health roadmap, India can safeguard its poultry sector and accelerate progress towards the goals of Viksit Bharat.

Poultry Sector and National Vision
The Indian poultry sector has emerged as one of the fastest-growing components of the livestock economy, contributing significantly to nutritional security, rural livelihoods, and national income. With over 6 million tonnes of chicken meat and more than 142 billion eggs produced annually, India ranks among the top poultry producers globally. However, the vision of Viksit Bharat 2047 emphasizes not just growth in numbers, but also sustainability, biosecurity, and resilience against diseases. Poultry flocks face major health threats from viral, bacterial, and parasitic infections, which can severely disrupt productivity. Vaccination is the most cost-effective and scientifically proven method to prevent infectious diseases in poultry. It not only safeguards flock health but also reduces dependency on antibiotics, thereby aligning with global efforts to combat antimicrobial resistance (AMR). In the Indian context, a robust vaccination strategy combined with innovative vaccine technologies is essential to ensure safe, sustainable, and globally competitive poultry production.

Major Poultry Diseases and Need for Vaccination

The Indian poultry industry is vulnerable to several devastating diseases that can wipe out entire flocks if not managed effectively. Newcastle Disease (Ranikhet), Infectious Bursal Disease (IBD or Gumboro), Marek’s Disease, Fowl Pox, Avian Influenza, Mycoplasmosis, Salmonellosis, and Coccidiosis remain primary threats. Outbreaks not only cause direct mortality but also result in poor feed conversion, reduced egg production, stunted growth, and increased veterinary costs. In a sector with narrow profit margins, even small disease outbreaks can push farmers into financial crisis. Vaccination is critical to prevent such losses and ensure predictable production. For example, ND vaccination is universally adopted in India, while IBD and Marek’s vaccines are routinely used in broiler and layer flocks. Vaccination also acts as a barrier against zoonotic diseases like Avian Influenza, which pose risks to human health. Beyond biological protection, vaccines are key to market access, as global trade standards demand disease-free certification. Thus, comprehensive vaccination programs serve as both a production necessity and a policy imperative for India’s poultry sector in its journey towards Viksit Bharat.

Current Vaccination Strategies in India
Presently, the Indian poultry industry relies on a mix of live attenuated, inactivated (killed), and recombinant vaccines. Day-old chicks are often vaccinated at hatcheries, while subsequent doses are administered at farms by trained personnel. Broilers typically receive vaccines against ND, IBD, and Marek’s, while layers undergo longer schedules covering Fowl Pox, Egg Drop Syndrome, and Salmonellosis. Commercial hatcheries have standardized protocols, but backyard and smallholder poultry systems still suffer from low vaccine coverage due to lack of access and awareness. Vaccines are usually delivered through drinking water, eye drops, intramuscular injections, or wing web methods. However, challenges persist in maintaining the cold chain, ensuring correct dosages, and preventing improper administration. Despite these limitations, vaccination coverage in commercial farms has improved significantly, leading to better flock health and reduced antibiotic dependence. Government agencies, private companies, and veterinary universities are working collaboratively to extend these benefits to rural poultry farmers. Standardized vaccination calendars tailored to regional disease prevalence can further improve efficiency. The existing strategies, though effective, need technological upgrades and equitable access to align with India’s aspirations of modern, climate-resilient, and globally integrated poultry production.

Limitations and Challenges of Conventional Vaccines
Despite their proven utility, conventional vaccines face several limitations in the Indian poultry sector. Live vaccines, while highly immunogenic, sometimes revert to virulence or interact with maternal antibodies, reducing their effectiveness. Inactivated vaccines, though safe, require multiple doses and are more expensive. In addition, improper handling—such as exposure to high temperatures during transportation—often compromises vaccine efficacy. A major challenge is the mismatch between circulating field strains and the strains used in commercial vaccines. For example, evolving variants of ND and IBD viruses occasionally bypass existing vaccines, causing outbreaks even in vaccinated flocks. Smallholder and backyard poultry, which form a substantial part of India’s rural economy, often remain unvaccinated due to cost, limited access, and lack of cold chain infrastructure. Moreover, conventional vaccines rarely provide sterilizing immunity, allowing vaccinated birds to shed pathogens silently, which complicates disease eradication efforts. In the backdrop of climate change, rising stocking densities, and globalization of poultry trade, these limitations demand next-generation vaccine solutions. To achieve Viksit Bharat, India must address these challenges by integrating science, technology, and farmer-centric delivery systems in its poultry vaccination programs.

Advances in New Vaccine Technologies
Recent scientific breakthroughs have paved the way for innovative vaccines tailored to modern poultry needs. Recombinant DNA vaccines, vector-based vaccines, immune-complex vaccines, and nanoparticle-based delivery systems are gaining traction. These technologies offer higher safety, broader protection, and longer-lasting immunity compared to traditional vaccines. For instance, recombinant vaccines can target multiple pathogens simultaneously, reducing the need for multiple injections. Immune-complex vaccines help overcome maternal antibody interference, ensuring early chick protection. Thermostable vaccines, currently being developed, can withstand higher temperatures, eliminating the need for stringent cold chains—a boon for rural and remote areas. Moreover, edible vaccines derived from transgenic plants and oral vaccines administered through feed or water provide farmer-friendly alternatives. The integration of nanotechnology has enhanced antigen stability and delivery, improving immune response. These innovations not only improve disease control but also align with sustainable and antibiotic-free poultry production systems. By adopting such advanced technologies, India can strengthen its poultry sector to withstand future disease challenges while ensuring affordability and accessibility for all categories of farmers.

Hatchery-Based and In-Ovo Vaccination

One of the most transformative innovations in poultry vaccination is hatchery-based immunization, particularly in-ovo vaccination. In this method, vaccines are delivered directly into the egg on the 18th day of incubation, before the chick hatches. This ensures early, uniform, and stress-free protection against diseases like Marek’s and ND. Automated in-ovo vaccination systems allow high-throughput immunization with minimal labour, ensuring biosecurity and accuracy. Post-hatch, chicks already possess robust immunity, reducing the risk of early chick mortality. This approach also minimizes handling stress, improving welfare and productivity. For commercial hatcheries in India, in-ovo vaccination holds immense promise in terms of scalability, cost-effectiveness, and alignment with global best practices. Hatchery vaccination of day-old chicks against ND, IBD, and Salmonella is already gaining popularity. As India modernizes its hatchery infrastructure under the Viksit Bharat framework, the integration of in-ovo technologies can revolutionize poultry health management. Expanding these practices to both commercial and rural hatcheries will ensure equitable benefits across the value chain. Thus, hatchery-based vaccination strategies represent a forward-looking step towards resilient poultry farming.

Role in Antibiotic Stewardship and AMR Reduction
The overuse of antibiotics in poultry has been a long-standing concern due to its contribution to antimicrobial resistance (AMR), which poses a global public health threat. Vaccination is a powerful tool in reducing reliance on antibiotics by preventing bacterial infections and associated secondary complications.
For example, vaccines against Salmonella, E. coli, and Mycoplasma significantly reduce the need for antibiotic treatments. In addition, viral vaccines indirectly lower antibiotic usage by reducing co-infections that would otherwise require antimicrobial intervention. India’s poultry sector is under increasing scrutiny from consumers, exporters, and regulators regarding antibiotic residues in meat and eggs. By adopting comprehensive vaccination programs and new-generation vaccines, the industry can move towards antibiotic-free poultry production systems, aligning with international standards. This is particularly crucial as India eyes larger export markets in the Middle East, Africa, and Asia-Pacific. Vaccination-led AMR stewardship is not just a health necessity but also a trade enabler and consumer confidence booster. Thus, vaccines play a pivotal role in aligning India’s poultry industry with the One Health approach and the national goal of Viksit Bharat.

Policy Support and Public-Private Partnerships
The success of vaccination strategies in India depends heavily on supportive policies, infrastructure, and partnerships. Government agencies like the Department of Animal Husbandry, ICAR institutes, and State Veterinary Departments must play a central role in disease surveillance, vaccine research, and farmer training. At the same time, private vaccine manufacturers, integrators, and farmer cooperatives need to collaborate in creating affordable and farmer-friendly solutions. Public-private partnerships (PPP) can accelerate the development of thermostable vaccines, indigenous recombinant vaccines, and scalable hatchery vaccination systems. Subsidies, credit support, and extension services should be provided to smallholder farmers to improve vaccine adoption. Strengthening diagnostic laboratories and surveillance networks will ensure vaccines are updated against circulating strains. Furthermore, India must harmonize its poultry vaccination policies with WOAH (World Organisation for Animal Health) and Codex standards to expand exports. By embedding vaccination strategies into national livestock and poultry development programs, policymakers can ensure that poultry contributes robustly to the nutritional, economic, and employment goals envisioned under Viksit Bharat.

Capacity Building and Farmer Awareness
A robust vaccination strategy is incomplete without farmer participation and awareness. Many disease outbreaks in India are linked to gaps in farmer knowledge about vaccine handling, schedules, and post-vaccination management. Training programs, mobile-based advisory services, and community-based poultry health workers can play an important role in bridging these gaps. Integrating digital tools like AI-driven vaccination calendars, blockchain-based cold chain monitoring, and mobile reminders can improve efficiency and compliance. Educational campaigns in local languages are needed to dispel myths about vaccination, such as misconceptions regarding reduced fertility or productivity. Special emphasis must be placed on women farmers, who play a crucial role in backyard poultry rearing but often lack access to formal veterinary training. Farmer cooperatives, SHGs (Self Help Groups), and FPOs (Farmer Producer Organizations) can act as vehicles for disseminating vaccination services at the grassroots. By building capacity and creating farmer-centric vaccination systems, India can democratize the benefits of new vaccine technologies, ensuring inclusive growth of the poultry sector.

Vaccination Roadmap towards Viksit Bharat
The future of India’s poultry sector lies in its ability to combine productivity with sustainability, resilience, and global competitiveness. Vaccination strategies and new vaccine technologies form the cornerstone of this transformation. From conventional vaccines to recombinant DNA vaccines, in-ovo immunization, thermostable formulations, and nanotechnology-driven innovations, the spectrum of tools available today is wider than ever. However, technology alone is not enough. Equitable access, policy support, capacity building, and farmer participation are equally vital. A national poultry vaccination roadmap aligned with Viksit Bharat 2047 should prioritize:

(I) strengthening surveillance and diagnostics,
(ii) promoting indigenous vaccine R&D,
(iii) scaling hatchery-based immunization,
(iv) supporting smallholder vaccination access, and
(v) integrating vaccination with AMR stewardship.

By embracing these strategies, India can ensure that its poultry sector not only meets the rising domestic demand for safe, affordable protein but also positions itself as a global leader in sustainable poultry production. Vaccination is more than just a disease-control measure; it is a strategic investment in the nation’s food security, public health, and economic prosperity.

Breathing Trouble: A Glimpse into the World of CRD in Poultry
India ranks second globally in egg production and fifth in poultry meat production. The Indian poultry market, despite being one of the largest globally, remains a developing sector due to its fragmented infrastructure, inconsistent biosecurity standards, and varying degrees of modernization across regions.

A significant portion of poultry production still relies on open housing systems, limited automation, and minimal veterinary oversight, especially among smallholder and backyard farmers. These conditions foster high disease prevalence, as poor sanitation, overcrowding, and lack of structured vaccination programs create ideal environments for the spread of infectious agents like Mycoplasma gallisepticum, E. coli, and coccidia. Consequently, the industry faces substantial economic losses through reduced productivity, higher mortality, increased medication costs, and trade restrictions. Bridging the gap between traditional practices and scientific poultry management is critical for improving flock health and sustaining long-term growth.

One Breath at a Time: Poultry Farmers Battle Chronic Respiratory Disease

Before any effective fight against Chronic Respiratory Disease (CRD) can begin, the poultry industry must first understand the enemy it faces. CRD is not just another seasonal illness—it’s a complex, persistent infection primarily caused by Mycoplasma gallisepticum, capable of silently spreading through flocks and leaving devastating economic consequences in its wake. Its symptoms often mimic those of other respiratory illnesses, making early detection a challenge. Without a clear understanding of its pathogenesis, transmission, and triggers, efforts to control CRD remain reactive and insufficient. Knowledge is the first line of defense—only with education, diagnosis, and structured prevention can farmers hope to break the cycle of recurring outbreaks. The battle against CRD must begin with awareness and be fought with science, vigilance, and unity across the industry.

Unmasking the Culprit: The Hidden Cause of CRD in Poultry

CRD is caused by Mycoplasma gallisepticum (MG), a wall-less bacterium that affects the respiratory tract of poultry. Secondary infections with Escherichia coli, Ornithobacterium rhinotracheale, and viral pathogens (NDV, IBV) often exacerbate disease severity.

Silent Spread: How CRD Continues to Lurk in Poultry Farms
CRD in poultry, caused by Mycoplasma gallisepticum, spreads through both horizontal and vertical transmission. Infected birds release the pathogen via respiratory secretions, contaminating air, water, feed, and equipment. Vertical transmission from breeder hens to chicks via eggs further fuels early infection. Recovered birds often remain silent carriers, shedding the organism under stress. This makes CRD hard to eradicate and highlights the need for strong biosecurity, breeder screening, and flock management to control its spread.

How CRD Takes Hold: Understanding the Disease’s Journey in Poultry
The pathogenesis of Chronic Respiratory Disease (CRD) in poultry begins when birds inhale aerosolized Mycoplasma gallisepticum, the primary causative agent. The pathogen adheres to the ciliated epithelial cells lining the upper respiratory tract, disrupting the mucociliary clearance mechanism. This allows the bacteria to colonize and multiply, triggering a chronic inflammatory response that leads to thick mucus secretion, tracheitis, and air-sacculitis. The damaged respiratory lining also becomes highly susceptible to secondary bacterial infections, particularly from E. coli, compounding respiratory distress and systemic illness.

In commercial poultry, stress factors such as poor ventilation, high stocking density, and concurrent viral infections (like IBV or NDV) can further exacerbate disease progression, resulting in reduced growth rates, poor feed conversion, decreased egg production, and increased mortality.

Signs & Symptoms with Postmortem (PM) Findings
CRD in poultry typically presents with a range of respiratory signs that can vary in severity based on age, immune status, and presence of co-infections. Common clinical signs include coughing, sneezing, nasal discharge, tracheal rales, conjunctivitis, reduced feed intake, stunted growth, and a noticeable drop in egg production in layers. Birds may also exhibit open-mouth breathing and watery eyes. In chronic stages, swelling of infraorbital sinuses and air-sacculitis becomes evident. On postmortem examination, the most consistent findings include thickened, cloudy air sacs (airsacculitis), catarrhal to caseous exudate in the trachea and bronchi, perihepatitis, pericarditis, and fibrinous pneumonia. In cases complicated by secondary infections like E. coli, lesions become more severe, showing a classic “CRD complex.”

Integrated Strategy to Fight CRD
An integrated CRD control strategy combines biosecurity, vaccination, early detection, nutritional support, and precision medication.

Preventive Phase: Reducing the Latent Load
Forlutin 10% (Tiamulin 10%) a high-quality feed additive by Stallen South Asia Pvt. Ltd. serves as the cornerstone for preventive management. Administering it to growers between 7 to 14 weeks of age or just before expected stress periods such as vaccination or peak lay helps reduce the latent load of Mycoplasma. This approach prepares the flock by lowering the pathogen load before the birds reach a vulnerable stage.

Outbreak Management: When Clinical Signs Appear
At the onset of clinical signs indicative of Mycoplasmosis, immediate action is required. Stalmicosin (Tilmicosin Phosphate 250mg) oral solution – a high-quality product manufactured by Stallen South Asia Pvt. Ltd. in its own manufacturing facility to ensure the highest Quality standards, administered via drinking water at 15–20 mg/kg body weight, is highly effective due to its deep lung penetration and prolonged action. This should be continued for 3 to 5 days but not exceeded.

Following the Stalmicosin course, a 24–48hour break should be observed before beginning treatment with Forlutin 80% (Tiamulin 80%) water soluble powder. A dosage of 25–50 mg/kg body weight for another 3 to 5 days helps eliminate residual Mycoplasma and prevents recurrence. Integrating these antimicrobials into a scheduled rotation can significantly reduce disease recurrence and resistance development.

Monitoring and Biosecurity: Supporting the Antimicrobial Strategy
Surveillance using PCR and ELISA tests at regular intervals is vital to detect Mycoplasma presence, especially during and after stress periods. Swab sampling and necropsy examinations for lesions such as air sacculitis or swollen joints provide further evidence. Strict biosecurity—enforcing all-in/all-out practices, staff segregation, and regular disinfection using NADCC, quaternary ammonium compounds, or glutaraldehyde—is essential to support the medical interventions.

References
1. Indian Journal of Veterinary Science & Poultry Health, 2023. Comparative Efficacy of Antibiotics in CRD.
2. Practical Poultry Guide, Vol 18, 2024 – Antimicrobial Resistance Trends in Poultry Pathogens.
4. McOrist et al. (2002) – Tilmicosin pharmacokinetics and tissue distribution in avian models.
5. Poultry Science Journal, 2022 – Mycoplasma Control Strategies in South Asia.